The vision of the Dissolution Working group is to form an industry position on how to select the most appropriate dissolution method to predict in-vivo performance, guide formulation development and support product registration.

The WG’s objectives include communicating the latest trend in biorelevant dissolution model; formulating an industry position on the role of QC and biorelevant dissolution in drug development; developing best practice for setting clinically relevant dissolution specification, and to be a joint force in leading the discussions with the FDA/EMA to advance the dissolution development.